翔泳社では、「独習」「徹底入門」「スラスラわかる」「絵で見てわかる」「一年生」などの人気シリーズをはじめ、言語や開発手法、最新技術を解説した書籍を多数手がけています。プロジェクトマネジメントやチームビルティングといった管理職向けの ...

ECLIPSE ABOUT WHAT SCIENTISTS ARE LOOKING FORWARD TO. WE ARE JUST DAYS AWAY FROM A RARE CELESTIAL EVENT A TOTAL ECLIPSE OF THE SUN ON APRIL 8TH. MORE THAN 31 MILLION PEOPLE WILL BE IN THE PATH OF ...

CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...

SAN FRANCISCO, March 13, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE ...

ECLIPSE registrational program now fully underway, following enrollment of the first patient in ECLIPSE 3 ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...

The sun is about to pull another disappearing act across North America, turning day into night during a total solar eclipse.The peak spectacle on April 8 will last up to 4 minutes, 28 seconds in the ...

The sun is about to pull another disappearing act across North America, turning day into night during a total solar eclipse.The peak spectacle on April 8 will last up to 4 minutes, 28 seconds in the ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and ...